Pathological characteristics of low risk prostate cancer based on totally embedded prostatectomy specimens

Prostate

Volumn 75, Issue 4, 2015, Pages 424-429

  Swanson, Gregory P ^a   Epstein, Jonathan I ^b   Ha, Chul S ^a   Kryvenko, Oleksandr N ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Gleason score 6; Multifocality; Prostate cancer; PSA; PSA density; Tumor volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BILATERAL CANCER; CANCER GRADING; CANCER RISK; CANCER STAGING; CAUCASIAN; GLEASON SCORE; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR BURDEN;

EID: 84920836559     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22928     Document Type: Article

References (18)

1. Ganz PA, Barry JM, Burke W, Col NF, Corso PS, Dodson E, Hammond ME, Kogan BA, Lynch CF, Newcomer L, Seifter EJ, Tooze JA, Viswanath K, Wessells H. National Institutes of Health State-of-the-Science Conference: Role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med 2012;156:591-595.
2. Epstein JI, Allsbrook WC, Jr., Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-1242.
3. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M. 3rd, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC. NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 2010;8:162-200.
4. Tosoian JJ, John Bull E, Trock BJ, Landis P, Epstein JI, Partin AW, Walsh PC, Carter HB. Pathological outcomes in men with low risk and very low risk prostate cancer: Implications on the practice of active surveillance. J Urol 2013;190:1218-1222.
5. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002;60:264-269.
6. Al-Hussain TO, Epstein JI. Initial high-grade prostatic intraepithelial neoplasia with carcinoma on subsequent prostate needle biopsy: Findings at radical prostatectomy. Am J Surg Pathol 2011;35:1165-1167.
7. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374.
8. Duffield AS, Epstein JI. Detection of cancer in radical prostatectomy specimens with no residual carcinoma in the initial review of slides. Am J Surg Pathol 2009;33:120-125.
9. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with Gleason score (GS) ≤ 6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 2012;36:1346-1352.
10. Kryvenko ON, Carter HB, Trock BJ, Epstein JI. Biopsy criteria for determining appropriateness for active surveillance in the modern era. Urology 2014;83:869-874.
11. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71:933-938.
12. Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RC, Hoedemaeker RF, van Leenders GJ, Schroder FH, van der Kwast TH. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011;185:121-125.
13. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996;275:288-294.
14. Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV. Impalpable invisible stage T1c prostate cancer: Characteristics and clinical relevance in 100 radical prostatectomy specimens-a different view. J Urol 1997;157: 244-250.
15. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: Lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001;166:104-109; discussion.
16. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB. Nonpalpable stage T1c prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;6:2407-2411.
17. Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, Koch MO. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 2005;18:1022-1026.
18. Sundi D, Kryvenko ON, Carter HB, Ross AE, Epstein JI, Schaeffer EM. Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black american men. J Urol 2014;191:60-67.